Encysive Pharmaceuticals (ENCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Encysive Pharmaceuticals (ENCY)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (11)	1/8/2006 10:36:36 PM
From: tuck	Read Replies (1) of 205

UTHR's inhalable Remodulin trial, called a PIII in the protocol: clinicaltrials.gov The trial started in June and uses a German made ultrasonic nebulizer, but in October they signed a deal with ARDM. phneighborhood.com So I gather the current trial is not pivotal, even though it's being called a PIII. After all, it only is recruiting 150 patients. It's been pointed out that the most direct current competition is for Thelin is Tracleer, in that they have similar MOAs. So one of these or a viagra with Remodulin or Ventavis. Those would be the specific combinations in early stage patients, right? BTW, drbio45 on Ihub confirms he meant congenital heart disease, not connective tissue disease. His analysis of the ARIES and STRIDE trials otherwise stands. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next